Innovent Biologics Inc. has announced a new compensation plan, effective June 30, 2025, under the 2024 Share Scheme. The company granted 35,000 share options to three grantees and 497,750 restricted shares to 25 grantees. These grants are contingent upon individual annual performance targets, which are aligned with specific functional benchmarks, such as research and development, CMC, and commercialization. Additionally, a clawback mechanism has been established, allowing the company to reclaim shares or cash if certain conditions are met, such as the grantee no longer being an eligible participant. The board, led by Chairman Dr. De-Chao Michael Yu, oversees the implementation of these new compensation terms.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.